Business
Lixa inks deal to progress trials, raise $28m
A company born out of UWA research and seeking to provide a circuit breaker to antimicrobial resistance will look to raise $28 million as it nears a crucial juncture of the preclinical stage.
A company born out of UWA research and seeking to provide a circuit breaker to antimicrobial resistance will look to raise $28 million as it nears a crucial juncture of the preclinical stage.
You must be logged in to post a comment Login